Trillium Therapeutics Total Liabilities

Trillium Therapeutics (TRIL) currently reports a total liabilities of $22M as of September 2021. That compares with $110M in the prior-year period — down 80.4% year over year. Use the charts on this page to explore Trillium Therapeutics's total liabilities history and peer comparisons.

Trillium Therapeutics's total liabilities decreased from $110M to $22M — a 80.4% year-over-year decrease (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Trillium Therapeutics reported $22M in total liabilities as of September 2021. That compares with $110M in the prior-year period — down 80.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $22M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Trillium Therapeutics, and consider following TRIL for alerts when major investors trade the stock.

Trillium Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $22M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRIL with unrelated industries.